Caris Life Sciences

Join Caris at the @isliquidbiopsy ISLB 2026 and connect with the global liquid biopsy community.

Visit Booth 5 to explore how comprehensive molecular profiling and liquid biopsy technologies are helping advance biomarker discovery, precision oncology and personalized treatment strategies.

Learn more: ow.ly/kCgx5104ILv

Myeloid malignancies are genetically complex and often require multiple assays. Caris ChromoSeq brings the full genomic landscape into one high-coverage Whole Genome Sequencing (WGS) test, supporting clearer diagnosis and risk stratification in a single report. Learn more: bit.ly/4ufznZw

The stage at which cancer is diagnosed shapes outcomes. For certain cancers, five-year survival rate can exceed 90% at Stage I and fall below 10% at Stage IV.

Caris Detect™ is a blood-based test designed to identify early-stage cancer signals, so patients can act sooner and increase there chances of survival.

Order the test: CarisDetect.com

Caris Life Sciences released its third-quarter financial results today, which included revenue growth of 27% and raises 2026 revenue guidance to $1.04 to $1.05 billion, representing growth of 28% to 29%.

Learn more: ow.ly/sq8a5103S1v

When tumor heterogeneity raises questions, are you confident in the risk assessment?
In a recent case of invasive lobular carcinoma, two distinct tumor regions showed discordant 21-gene assay scores.

Caris MI Clarity™ evaluated two distinct tumor blocks and produced concordant early- and late-risk classifications, providing greater confidence that the reported risk reflected the patient's underlying disease risk.

Learn more about how MI Clarity helped answer a challenging clinical question: ow.ly/QA3t50ZHLwL